Response to HBI0101 therapy by RF groups. ORR (A,D,G), PFS (B,E,H), and OS (C,F,I) were estimated in patients receiving HBI0101 infusion, according to HR cytogenetics (A-C; n = 12), EMD presentation (D-F; n = 16), and the number of CAR⁺ T_EMs in CART FP above the median (>5.7 × 10⁸ CAR⁺ T_EMs) (G-I; n = 23). In panel 3G, the percentages for CR, VGPR, and PR do not add up to the percentage atop the bar graph due to rounding. Pink lines indicate patient group with RF, and blue lines indicate patient group without RF.